CD19 and graft versus host disease: In this study, a comprehensive preclinical safety assessment of CD19‐CAR‐DNTs was performed using NOG mice, and it was further confirmed that no signs of immunotoxicity or GvHD were observed in the non‐tumor‐bearing mice treated with CD19‐CAR‐DNTs.